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Managing multimorbidity in primary care in patients
with chronic respiratory conditions
Deborah Morrison1, Karolina Agur1, Stewart Mercer1, Andreia Eiras2,3,4, Juan I González-Montalvo5 and Kevin Gruffydd-Jones6
The term multimorbidity is usually deﬁned as the coexistence of two or more chronic conditions within an individual, whereas the
term comorbidity traditionally describes patients with an index condition and one or more additional conditions. Multimorbidity of
chronic conditions markedly worsens outcomes in patients, increases treatment burden and increases health service costs.
Although patients with chronic respiratory disease often have physical comorbidities, they also commonly experience psychological
problems such as depression and anxiety. Multimorbidity is associated with increased health-care utilisation and speciﬁcally with an
increased number of prescription drugs in individuals with multiple chronic conditions such as chronic obstructive pulmonary
disease. This npj Primary Care Respiratory Medicine Education Section case study involves a patient in a primary care consultation
presenting several common diseases prevalent in people of this age. The patient takes nine different drugs at this moment, one or
more pills for each condition, which amounts to polypharmacy. The problems related with polypharmacy recommend that a
routine medication review by primary care physicians be performed to reduce the risk of adverse effects of polypharmacy among
those with multiple chronic conditions. The primary care physician has the challenging role of integrating all of the clinical
problems affecting the patient and reviewing all medicaments (including over-the-counter medications) taken by the patient at any
point in time, and has the has the key to prevent the unwanted consequences of polypharmacy. Multimorbid chronic disease
management can be achieved with the use of care planning, uniﬁed disease templates, use of information technology with
appointment reminders and with the help of the wider primary care and community teams.
npj Primary Care Respiratory Medicine (2016) 26, 16043; doi:10.1038/npjpcrm.2016.43; published online 15 September 2016
CASE STUDY
Mr A is a 65-year-old unemployed man who lost his job a year
ago, having been a factory worker for many years. He is
married and lives in subsidised public housing. His wife was
diagnosed with breast cancer 9 months ago, and underwent a
mastectomy and chemotherapy but is now doing well.
They have two grown-up children, both living overseas. He was
recently diagnosed with chronic obstructive pulmonary disease
(COPD).
His main complaint at these recent consultations has been a
productive cough and shortness of breath especially at night.
His sleep has been poor, which he relates to his cough. Sometimes
he takes medication to be able to have a full night’s sleep.
He is also known to have hypertension, and general osteoarthritis
affecting several joints and the back. He had a myocardial
infarction 18 months ago, and was also found to have mild
heart failure (left ventricular systolic dysfunction). He is on
numerous medications, including inhalers and tablets (see the
table below). He continues to smoke 420 cigarettes per day and
admits to drinking more alcohol recently, as he feels it helps
him sleep.
Sometime after his wife was diagnosed with cancer, shortly
after his myocardial infarction, he was prescribed anti-depressive
medication, which he takes irregularly, as well as a tablet to help
him sleep.
He has different annual reviews by different practices nurses for
his different long-term conditions. He often does not turn up for
these booked reviews.
Mr A’s usual medication
Problem Medication
Hypertension Lisinopril 20 mg, 1 daily
General osteoarthritis Diclofenac 75 mg as needed
Coronary heart disease/heart
failure
Acetylsalicylic acid 75 mg, 1 daily, simvastatin 20 mg,
1 daily
Bisoprolol 2.5 mg, 1 daily
COPD Tiotropium 2.5 μg, 1 puff daily,
Salbutamol 100 μg, 2 puffs as needed
Depression/sleep problems Sertraline 50 mg, 1 daily
Zolpidem 5 mg occasionally
Alcohol/smoking No medication/brief advice
THE EPIDEMIOLOGY OF MULTIMORBIDITY IN CHRONIC
RESPIRATORY CONDITIONS
This case involves a patient in a primary care consultation presenting
with at least six common diseases prevalent in people of this age.
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MULTIMORBIDITY
The term multimorbidity is usually deﬁned as the coexistence of
two or more chronic conditions within an individual, whereas the
term comorbidity has traditionally been used to describe patients
with an index condition (such as asthma) and one or more
additional conditions.1 Multimorbidity is becoming the preferred
terminology in primary care, where the deﬁnition of an index
condition is less meaningful. The prevalence of multimorbidity has
doubled over the last 20 years,2 and in many countries is now the
norm rather than the exception in the elderly and in patients with
chronic disease.3,4 Multimorbidity is associated with lower quality
of life, lower physical function, higher mortality rates,5 and also
increased polypharmacy and higher acute admission rates,6 all of
which lead to increased burdens for patients and contribute to
increased costs for health-care providers. There is a lack of
consistency in the prevalence rates described in the literature. This
can be partially explained by variable disease reporting methods,
the number of conditions ‘included’ and the type of populations
studied. However, studies consistently show that multimorbidity
increases with age.3,4 However, this does not mean that multi-
morbidity is only an older person’s problem. In many countries
there are more people under the age of 65 years living with
multimorbidity than over.3,4,7
MULTIMORBIDITY AND RESPIRATORY CONDITIONS
Asthma
Respiratory conditions are among the most common chronic
conditions in patients with multimorbidity. In a nationally
representative primary care study of 1.75 million people in
Scotland, currently treated asthma had a prevalence of 6% and
(despite the fact that asthma affects many children) 52% of
individuals with asthma had one or more additional conditions.3
The most common comorbidities in this Scottish study are
shown in Table 1. Similar ﬁndings have been reported in other
population-based surveys.8,9 For example, Steppuhn et al.9
recently conducted a national survey of 43,312 people in Germany
in which 1,134 individuals reported asthma (5%) and found that
58% of those with asthma had at least one comorbidity. Having
three or more chronic conditions was more than twice as common
in those with asthma (17%) compared with those without asthma
(8%). Zhang et al.8 conducted a survey of 132,221 Canadians aged
12 years and over, of whom 10,089 (8%) had asthma, and reported
that 59% of those with asthma had at least one other chronic
illness. After adjusting for age and gender, all major chronic
conditions except cancer were more common in those with
asthma than in those without, similar to ﬁndings reported by
Steppuhn et al.
As with other studies,10 Steppuhn et al. also comment that
comorbidities in asthma are not limited to the elderly, showing
that over 30% of those aged 18–44 with asthma have at least one
other chronic condition.9 This raises concerns that these younger
patients may be on a trajectory towards higher burdens of
multimorbidity as they age.10 Comorbidity in asthma appears to
lead to worse outcomes, with higher risk for exacerbations,8
unscheduled care9 and mortality.11
Chronic obstructive pulmonary disease
In the study by Barnett et al.,3 COPD had a prevalence of 3%, and
82% of these patients had two or more additional conditions
(47% had three or more); however, there are wide variations in the
prevalence rates of COPD, never mind multimorbidity prevalence
rates, making it impossible to conﬁdently provide a true
ﬁgure.12,13 The most common comorbidities in the Scottish study
are shown in Table 1. A study in Ireland found that 60% of patients
with chronic respiratory disease had at least one or more other
chronic conditions, rising to 90% among individuals over 70 years
of age.14 COPD is predicted to be the third leading cause of death
globally by 2020,15 and mortality rates in chronic respiratory
conditions are substantially increased by comorbidities.16 The
number of comorbidities in patients with COPD is also related to
worse symptom control and more exacerbations.17 The same
study also showed that the type of morbidities commonly
associated with COPD were often life-threatening conditions such
as ischaemic heart disease (present in almost 24% of COPD
patients).
COPD is also associated with polypharmacy and this will be
substantially increased in those with comorbidities, thus increas-
ing the risk for adverse drug reactions, drug–drug interactions and
drug–disease interactions. This can increase the treatment burden
as well as lower medication adherence.18 In addition, health
professionals may under-prescribe for one condition (e.g., beta-
blockers for cardiac disease) for fear of causing worsening
respiratory symptoms when both conditions are present, leading
to patients missing out on potentially beneﬁcial medications, as
seen in the case study where his bisoprolol dose is likely to be
suboptimal.
RESPIRATORY DISEASE AND COMORBID MENTAL HEALTH
CONDITIONS
Although patients with chronic respiratory disease often have
physical comorbidities, they also commonly experience psycho-
logical problems such as depression and anxiety. It has been
reported that up to 25% of people with COPD19,20 and 13–14% of
people with asthma9,21 have depression, whereas only 7% of
people without these chronic respiratory conditions have
depression. The presence of mental health conditions negatively
inﬂuences the outcome for chronic conditions including exacer-
bations and acute admissions.6,9,21–25
It is interesting to note that depression is among the top ﬁve
comorbidities in both asthma and COPD, along with chronic pain
(Table 1).
The relationship between chronic respiratory disease (and
indeed most chronic diseases) and mental health problems is
likely to be bidirectional; patients with chronic respiratory
conditions may develop depression and anxiety as a result of
their respiratory conditions, perhaps due to functional limitations,
inability to work, etc. Patients with mental health conditions are at
a high risk of developing chronic physical conditions, because of
Table 1. Most common comorbidities in asthma and COPD
Most common comorbidities in patients with asthma
Hypertension 17,000 16.2%
Depression 14,662 14.0%
Pain 13,480 12.8%
Bronchitis 12,030 11.5%
Dyspepsia 9,313 8.9%
Most common comorbidities in patients with COPD
Hypertension 18,349 32.9%
Pain 12,720 22.8%
CHD 10,813 19.4%
Depression 9,997 17.9%
Dyspepsia 7,123 12.8%
Unpublished data from the data set reported in Barnett et al.3 based on a
nationally representative sample of 1,751,841 primary care patients in
Scotland, which had a total of 105,054 (6%) patients with asthma and
55,792 (3.2%) with COPD. The results above are for all patients with the
index condition (asthma or COPD).
Abbreviations: CHD, coronary heart disease; COPD, chronic obstructive
pulmonary disease.
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lifestyle factors such as higher rates of smoking. Smith et al.,26 for
example, reported that patients with depression have a 70–80%
increased risk of having asthma or COPD.
GENDER
Previous studies have shown that multimorbidity is generally
more prevalent in women than in men.4 Asthma tends to be more
prevalent in women than in men,27 whereas historically COPD
tended to have the opposite gender balance,28 although there is
evidence that this trend is starting to reverse.29,30 To date,
however, there is no clear evidence of a difference in the rates of
comorbidity by gender, speciﬁcally in those with asthma.8,9 This is
in contrast to COPD, in which gender differences in comorbidity
have been reported,31 ﬁnding a mean number of comorbidities of
4.6 (s.d. 3.2) for females and 6.2 (s.d. 3.5) for males (Po0.001).
MULTIMORBIDITY AND SOCIOECONOMIC STATUS
The prevalence of multimorbidity is socially patterned, being
higher in people of lower socioeconomic status.4 People living in
areas of high socioeconomic deprivation develop multimorbidity
10–15 years earlier than those living in afﬂuent areas.3 This
relationship between deprivation and multimorbidity is particu-
larly visible in patients with a combination of mental and physical
health problems, with a two- to threefold greater prevalence of
mental–physical multimorbidity in deprived areas compared with
afﬂuent areas.3,10 This is reﬂected in respiratory diseases; for
example, 23% of patients with COPD living in deprived areas have
diagnosed depression, compared with 14% of COPD patients in
afﬂuent areas.3 Again a similar picture is seen with asthma, where
lower levels of educational attainment are associated with
comparatively high rates of 3+ comorbidities.9 A further study
using administrative data from 34,741 Canadian patients aged
18–70 years with obstructive respiratory disease (asthma and
COPD combined) demonstrated a relationship between socio-
economic status (deﬁned by income quintile) and comorbidity,
with lower socioeconomic status individuals having three times
the levels of high comorbidity (⩾4) compared with those within
the higher socioeconomic groups (7.4% vs. 2.5%, respectively).32
FUTURE CHALLENGES
Multimorbidity of chronic conditions, including respiratory condi-
tions, markedly worsens outcomes for the patients, increases
treatment burden and increases health service costs.33 There are
very few interventions in primary care speciﬁcally developed for
patients with multimorbidity in general or with respiratory disease
in particular. Indeed, many trials exclude such patients. Thus,
guidelines are based on the evidence that may or may not be of
relevance in patients with respiratory conditions, and recommen-
dations rarely take account of multimorbidity. The importance of
the generalist clinician, who can deal effectively with complexity
and manage not just respiratory conditions but also the associated
physical, mental and social comorbidities, cannot be over-stated.
This is especially true in areas of high deprivation, given the social
patterning of multimorbidity and its burden.
Epidemiological studies of multimorbid patients, especially
those of a longitudinal nature, may help researchers identify
target groups and fruitful areas for intervention. Interventions are
likely to be complex and will require appropriate methodologies
to evaluate them. Increasingly, this will probably require mixed-
methods approaches and cost-effectiveness evaluation.
MULTIMORBIDITY AND POLYPHARMACY
Multimorbidity is associated with health-care utilisation and
speciﬁcally with an increased number of prescription drugs in
individuals with multiple chronic conditions such as COPD.34
Mr. A takes nine different drugs at this moment, one or more pills
for each condition, which amounts to polypharmacy.
There is no consensus in deﬁning polypharmacy, but commonly
used deﬁnitions are ‘45’ or 410 medications taken regularly by
an individual, and is a common situation among older people.35
In clinical practice, polypharmacy is the rule in patients with
cardiac and respiratory diseases. Patients with cardiac conditions
such as heart failure and coronary artery disease currently receive
multiple drugs simultaneously for controlling both the main
condition and risk factors. In respiratory diseases such as COPD
several drugs are frequently needed to improve control of
the symptoms, and polypharmacy is commonly used, which
substantially contributes to direct medical costs in COPD.36
Overuse of respiratory medication is an important risk factor for
adverse effects.37 Polypharmacy and the prescription of multiple
daily doses contribute to poor patient adherence in COPD, which
is a major concern.38
Although polypharmacy with respiratory drugs is an indicator of
poor health status in COPD, a direct negative effect of multiple
medications on health status cannot be excluded. Polypharmacy is
associated with poor self-rated health status among all age groups
in the general population.37
Older people are the main consumers of drugs due to the
increasing incidence of chronic disease with advancing age.39
Pharmacotherapy in the elderly requires knowledge of the age-
dependent changes in pharmacokinetics and pharmacodynamics,
as well as an assessment of comorbidity and concurrent drug
therapy to reduce adverse effects.
The factors predisposing to polypharmacy are poor health,
multiple chronic diseases, multiple prescribing physicians, the
patient’s expectations (e.g., in relation to therapeutic advances)
and education, an increasing demand for health care, supple-
mental insurance, and reluctance to discontinue old medications.
Polypharmacy increases the risk for inappropriate medications,40
Table 2. Inappropriate prescription in respiratory pharmacology: START and STOPP criteria
STOPP START
Drug prescriptions potentially inappropriate in persons aged
⩾ 65 years
Medications to be considered for people aged ⩾ 65 years with the following
conditions when no contraindications to prescription exist
1. Theophylline as monotherapy for COPD 1. Regular inhaled β2-agonist or anticholinergic agent for mild-to-moderate
asthma or COPD
2. Systemic corticosteroids instead of inhaled corticosteroids for
maintenance therapy in moderate-to-severe COPD
2. Regular inhaled corticosteroid for moderate-to-severe asthma or COPD
when the predicted FEV1o50%
3. Nebulised ipratropium with glaucoma 3. Continuous oxygen at home with documented chronic type 1 respiratory
failure or type 2 respiratory failure
Abbreviations: COPD, chronic obstructive pulmonary disease; STOPP, Screening Tool of Older Persons’ Prescriptions; START, Screening Tool to Alert doctors to
the Right Treatment.
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nonadherence to treatments, morbidity, mortality and adverse
drug reactions.37
Depending on the circumstances (e.g., why and how drugs are
being administered), polypharmacy can be appropriate (potential
beneﬁts outweigh potential harms) or inappropriate (potential
harms outweigh potential beneﬁts).35
POTENTIALLY INAPPROPRIATE MEDICATION: CURRENT TOOLS
Inappropriate prescribing in the elderly population is an emerging
health issue and comprises the following: use of an inappropriate
dose, formulation, duration and delivery of drugs; use of
unnecessary drugs; omission of necessary medicines; and the risk
of drug interactions and adverse drug events.39 Errors in
prescribing and in the omission of medicines are highly prevalent
among medically stable older people in primary care as well.41
Inappropriate medications may be detected with screening
tools for the assessment of the quality and safety of prescriptions.
The Beers criteria42 constitute one of the most widely used tools
for assessing the inappropriateness of prescriptions. They were
published in 1991, revised in 1997, and updated in 2002 and 2012.
The 2002 updated version was designed for all older people and
not just for nursing home residents (as were the two previous
versions).43 An alternative is the STOPP (Screening Tool of Older
Persons’ Prescriptions) and START (Screening Tool to Alert doctors
to the Right Treatment) criteria.44
Respiratory pharmacology is under-represented in the 2012
Beers criteria and, in the 2002 version of the list, propranolol and
long-acting benzodiazepines (chlordiazepoxide, chlordiazepoxide-
amitriptyline, clidinium-chlordiazepoxide, diazepam, quazepam,
halazepam and chlorazepate) are identiﬁed as inappropriate
prescriptions for older adults with COPD, although benzodiaze-
pines may be used to palliate intractable breathlessness. They do
not sufﬁciently address other drug–disease interactions, drug
misuse and under- or overprescribing.
Mr. A takes zolpidem irregularly; in the Beers criteria, although
comparable to benzodiazepine, it is included in the non-
benzodiazepine hypnotics group, which is not considered
inappropriate medication speciﬁcally in the context of COPD
disease. It is considered inappropriate medication if taken for
490 days, independently of the clinical presence of COPD.
The STOPP and START criteria are able to detect inappropriate
medications (drug class duplication and drug–drug and drug–
disease interactions) and the omission (or underprescription) of
indicated drugs, respectively. They have shown better sensitivity
than the Beers criteria in identifying prescription problems and in
identifying patients who required hospitalisation as a result of
inappropriate prescription-related adverse events.45 The START
criteria can help clinicians consider the beneﬁt (or otherwise) of
starting new drugs in complex clinical situations. The main
principles in correctly prescribing for COPD with STOPP/START
criteria are summarised in Table 2.
Mr. A already takes an inhaled β2-agonist and anticholinergic
agent according to the START list (Table 3). Use of these screening
tools can help prevent inappropriate prescriptions and improve
appropriate prescribing with a reduction in adverse drug events,
costs, nonadherence and polypharmacy.
COMPLIANCE
Polypharmacy hinders compliance with drug treatment. Patient
adherence to prescribed drugs has been shown to be low,
especially in long-term treatment.46 Nonadherence to treatments
can be inﬂuenced by several factors such as the complexity
of the dosing schedule, frequent changes in medication,
multiple medication, side effects, the cost of drugs, difﬁcult
routes of administration, difﬁcult-to-open containers, cognitive
impairment, visual impairment, inadequate patient education or
understanding, and the impairment of physical function.47
Inhalation is the preferred mode of delivery for many drugs in
the treatment of airway diseases such as COPD. The advantage of
this route is the delivery of drugs to the site where they are
needed. As a result, it allows smaller doses to be administered,
which are effective with a much lower risk for side effects,48 which
may improve patient compliance.
Table 4. Mnemonics to reduce polypharmacy in the elderly (adapted from Skinner et al.)56
SAIL (1998) S simple; prescribing drugs that can be taken once a day or adding a combination pill when a second pill must be added keeps a
patient’s drug regimen uncomplicated.
A adverse; the clinician must have knowledge of the adverse effects of all the drugs a patient is taking to avoid medication
interactions
I indication; there must be a clear indication for each drug a patient is taking with a desired therapeutic goal in mind
L is for list; the patient’s medication list must be accurate, including OTC products, herbs, and alternative medications, and must
correspond to their medical diagnoses.
ARMOR (2009) A assess the individual for the total number of medications and for certain groups of medications that have potential for adverse
outcomes in the older adult, such as beta-blockers, antipsychotics and antidepressants
R review for possible drug–drug, drug–disease and drug–body interactions
M minimise nonessential medications that lack a clear indication; the risks outweigh the beneﬁts that could have a negative
outcome on primary
functions such as appetite, bladder/bowel, activity and mood
O optimise by addressing duplication of drugs, adjustment of drugs for renal and hepatic function, reducing oral hypoglycaemia,
and monitoring anticoagulants and seizure medications carefully
R reassessment of the patient’s vital signs, cognitive status, function and medication compliance
TIDE (2012) T time; allow sufﬁcient time to address and discuss medication issues during each encounter
I individualise; apply pharmacokinetic and pharmacodynamic principles to regimens by adjusting doses for renal and hepatic
impairment and starting medications at the lowest effective dose
D drug interactions; consider potential drug–drug and drug–disease interactions
E educate; educate the patient and caregiver about non-pharmacological and pharmacologic treatments along with side effects
and monitoring parameters
MASTER (2011) M minimise drugs used
A alternatives that should always be considered, especially non-drug therapies
S start low and go slow
T titrate therapy, adjusting dose based on individual response
E educate the patient and family member with clear, written instructions
R review regularly
Managing multimorbidity in patients with respiratory conditions
D Morrison et al
5
Published in partnership with Primary Care Respiratory Society UK npj Primary Care Respiratory Medicine (2016) 16043
Inhaled drugs can be delivered by nebulisers, pressurized
metered-dose inhalers (pMDI), dry-powder inhalers (DPI) and soft
mist inhalers. Moreover, therapeutic efﬁcacy depends on ade-
quate airway drug deposition, which is inﬂuenced by particle size
and inhalation techniques. A pMDI requires good actuation/
inhalation coordination for optimal lung deposition, often difﬁcult
for elderly patients. The soft mist inhaler requires a slow, deep
breath, whereas a DPI requires sufﬁcient inspiratory ﬂow.
The inability to produce an adequate peak inspiratory ﬂow is
critically important. Both physiological age-related changes and
airway diseases can lead to weak inspiratory manoeuvres. The age-
related reduction in thoracic compliance and in diaphragmatic
strength associated with the COPD-related decline in inspiratory
muscle function due to lung hyperinﬂation can impair the generation
of an adequate peak inspiratory ﬂow. Further difﬁculties with the
delivery devices may arise because of visual limitations, cognitive
deterioration, poor coordination and arthritis, which impair device
handling, which could be a hindrance to optimum disease control in
patients with multimorbidity.49
Mr. A smokes and takes both a short-acting β2-agonist and a
long-acting anticholinergic for the treatment of his COPD. If more
than one drug is indicated, the use of combination inhalers
of long-acting β2-agonist and long-acting anticholinergic or
long-acting β2-agonist and inhaled steroids increases adherence
to the treatment.
Re-evaluate the COPD category, and, if clinically appropriate
and necessary, changing to a combination of long-acting
β2-agonist/long-acting anticholinergic in a single inhaler might
be more effective at producing maintained symptom relief than
short-acting bronchodilators, and the convenience might improve
compliance.
ADVERSE DRUG REACTIONS
In the elderly, the use of numerous medications associated with
pharmacokinetic and pharmacodynamic changes can lead to
adverse drug reactions, deﬁned as any injury resulting from drug
therapy.49 These may be drug–drug interactions, drug–disease
interactions, drug–food interactions or drug–herb interactions.39
The risk of these events is exacerbated by the impairment of
homeostatic mechanisms, by multimorbidity, and as a result older
people are more prone to adverse drug reactions and, generally,
these are more severe.50 Adverse drug reactions are a leading
cause of hospitalisation, mortality, falls, fractures and hypoglycae-
mia, but symptoms are not always reported by patients as they are
often mistaken for the symptoms of multiple diseases or with
ageing. Prescribing the lowest effective doses of medication to
elderly patients can help avoid adverse drug reactions, minimise
side effects and thus encourage compliance.51 It is appropriate to
remember the old aphorism ‘start low and go slow’.
Mr A is on a long-acting anticholinergic and we need to ask
speciﬁcally about the most common adverse events: dry mouth,
constipation, headache, pharyngitis and urinary retention. A slight
increase in the risk for cardiovascular events has been found in the
past with inhaled anticholinergic drugs52 and the risk/beneﬁt
balance needs to take into account his coronary heart disease.
Recent reviews found a wide disparity in ﬁndings among the
published studies evaluating the cardiovascular risks of inhaled
anticholinergic agents.53 Tiotropium has no frequent inhibitory
effect on cytochrome P450 isozymes and no clinically signiﬁcant
interactions have been reported.54 On the other hand, no studies
Figure 1. Patient-centred approach for the assessment of patients with COPD.
Presenng problems
Cough
Insomnia
Connuing problems
Hypertension/ischaemic heart disease /heart failure
COPD
Osteoarthris
Depression
Mulple drug therapy and poor compliance (with drugs and appointments)
Connued smoking and excess alcohol intake 
Social factors
Unemploymnt- loss of self-esteem, potenal ﬁnancial concerns
‘Carer’ needs (In this case who is the carer?)
Shortness of breath 
Figure 2. Issues for the consultation arising out of the case vignette.
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have been found in the literature on the effect of age and severe
renal or hepatic impairment on tiotropium pharmacokinetics.54
Notwithstanding the low oral bioavailability, inhaled β2-agonists
have the potential to cause systemic adverse effects; therefore,
we have to look for symptoms such as tremor, tachycardia,
palpitations and changes in blood glucose or plasma potassium
concentrations.54
MINIMISING MEDICATION PROBLEMS
A regular medication review by primary care physicians should be
performed to reduce the risk for polypharmacy among those with
multimorbidity.55 Nine key questions have been suggested56 that
we should always ask our patients before a new prescription or at
least once a year (Table 4):
1. Is each medication necessary?
2. Is the drug contraindicated in the elderly?
3. Are there duplicate medications?
4. Is the patient taking the lowest effective dosage?
5. Is the medication intended to treat the side effect of another
medication?
6. Can the drug regimen be simpliﬁed?
7. Are there potential drug interactions?
8. Is the patient adherent?
9. Is the patient taking over-the-counter medication, a herbal
product or another person’s medication?
Prescribing for multimorbid—and especially elderly—patients
requires a careful and case-by-case assessment of the following
speciﬁc elements: pharmacokinetics, pharmacodynamics, poly-
pharmacy, comorbidity, adverse drug reactions, drug interactions,
the delivery system, and the social and economic factors that
affect nutrition and medication adherence.56 All of these factors
can have an impact on outcomes.
The primary care physician has the challenging role of
integrating all the clinical problems affecting the patient and
reviewing all the medications taken by the patient at any point in
time. This is the key to preventing polypharmacy and its
consequences.
HANDLING COMPLEX CONSULTATIONS ON COMORBIDITY
Mr A may present to the practice in one of three ways: (a) as an
acute presentation of one of his symptoms—e.g., breathlessness;
(b) with persistent chronic symptoms (in his case, cough,
breathlessness and insomnia); or (c) for routine review. This
commentary will focus on the latter two types of consultation.
CONSULTATION MODELS:
The Stott and Davis model57 for the consultation prioritises four
aspects of consultation:
● Dealing with the primary complaint (in this case scenario,
symptoms of breathlessness, cough and insomnia).
● Management of the continuing problems (COPD and the
multimorbidities).
● Using the consultation for opportunistic health promotion
(e.g., giving up smoking and reducing alcohol consumption).
● Modiﬁcation of health-seeking behaviour by encouraging
supported self-management.
The consultation model of Pendleton et al.58 sets out seven
‘tasks’ for the consultation based around recognising the patient’s
agenda—i.e., what they want out of the consultation, the effect of
the problem (insomnia, breathlessness and cough) on the
patient’s life and the production of shared management decisions.
In the United Kingdom, doctors receive payments under the
Quality and Outcomes Framework, which rewards practices for
ticking process boxes.59 For example, has the FEV1 or blood
pressure been checked? As a consequence, chronic disease
reviews tend to be driven by ‘ticking boxes’, risking neglect of
the patient perspective.
ISSUES FACED BY THE DOCTOR AND PATIENT IN A
CONSULTATION WITH MULTIMORBIDITY
The PCRS-UK assessment algorithm for patients with COPD
(Figure 1) taken from ‘The Diagnosis and Management of COPD
in primary care’60 promotes a patient-centred approach to care,
including a section on ‘holistic care’. This emphasises the
importance of multimorbidities and psychosocial problems,
including the needs of any caregivers.
From the information in the case vignette the issues appear to
be as shown in Figure 2.
It is impossible to deal with these problems in the usual 10-min
general practitioner consultation in the United Kingdom or even
in a 20-min chronic disease management review by the practice
nurse. Repeated attendance for multiple disease-speciﬁc chronic
reviews is due to inefﬁcient use of time by the primary care team
and can be hugely inconvenient for the patient. So how might this
practical problem be overcome?
Preliminary consultaon with nurse
Basic tests carried out determined 
by comorbidies present: blood tests, 
spirometry, quesonnaires
(e.g, COPD Assessment test)
Results sent to paent 
Highlighng abnormalies 
(? Sent electronically)
Paent decides on priories
Extended consultaon with GP
Shared decision making 
Health promoon 
Referral to primary           Roune follow up Referral to 
Care team, e.g, specialist  team 
pharmacist, social  
worker, psychologist
Figure 3. A model of care planning for patient with multimorbidity.
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MANAGING MULTIMORBIDITY IN PRIMARY CARE
The following is derived from an excellent recent review article in
the BMJ,61 ‘Managing multimorbidity’ in primary care, and also
from a survey of UK practices that illustrates how practices are
carrying out chronic disease reviews on patients with COPD and
multimorbidities.62
A Cochrane review of interventions to improve outcomes in
patients with multimorbidity in primary care illustrated the paucity
of studies available.63 The limited evidence available shows that
interventions are more successful if they deal with functional
outcomes (‘how much more can you do’) rather than disease-
speciﬁc outcomes. Also interventions that deal with common risk
factors (in this case, vignette smoking and alcohol) can be
successful.
The management of Mr A will depend on the timing of
consultations and the organisation of care in different general
practice surgeries. However, the general principles are likely to
follow the Stott and Davies Model.
Investigation of the presenting problem: on the surface, this is
likely to be cough and breathlessness, but the most pressing issue
for the patient may be his tiredness, depression or insomnia.
Initial consultation: the history, examination and initiation of
investigations (e.g., chest X-ray and full blood count) of the
presenting complaint will be the main priority.
Ongoing problems: the medical and psychosocial comorbidities
outlined in Figure 2 are likely to require an extended follow-up
consultation with the general practitioner where issues such as
polypharmacy can be addressed. It is important that Mr A see the
same doctor to ensure continuity of care and maximise the
success of any intervention.
HEALTH PROMOTION/OPPORTUNISTIC SCREENING
Once all the medical and psychosocial factors have been taken
into consideration the barriers to dealing with Mr. A’s excess
alcohol intake, smoking and non-attendance can be more easily
addressed. It might be possible to draw up a shared management
plan based on Mr. A’s views and priorities.
Effective management of the various problems is likely to
involve referral to other members of the primary health-care team
(e.g., social worker, psychological counsellor and smoking cessa-
tion services) and attendance for chronic disease management
checks encouraged by combining the nurse-led reviews of his
COPD, heart failure and hypertension.
ORGANISATIONAL FACTORS
The following have been used to improve the managements of
patients with multimorbidity:62,63
● Increasing continuity of care by seeing the same doctor/
practice nurse for review.
● Having speciﬁc extended consultation times (e.g., 30 min) for
patients with complex problems.
● Use of postal, telephone and text reminders for appointments.
● Use of a common chronic disease management template
that ideally can be shared with secondary and community
care teams.
● Involvement of other members of the primary health are team
—e.g., social worker, practice-attached psychologist, pharmacist
and smoking cessation service.
● Involvement of specialist community teams in the multi-
morbidity clinic.
● Housebound or nursing home patients often have complex
problems, and models of care include review by a named GP,
district nurse or community matron.
SHARED DECISION-MAKING
This involves the patient in management decisions within the
consultation. A speciﬁc model using ‘Ariadne Principles’ has been
devised for multimorbid consultations.64 This involves:
● Setting realistic targets (e.g., improving breathlessness so that
the patient can walk to the car).
● Prioritising the problems that the patient has (‘Most of all I want
to improve my insomnia’).
● Developing a management plan after discussing options with
the patient.
A good opening question could be ‘What is bothering you
most?’ or ‘What would you like to focus on today?’
A development in patient-centred care in the context of chronic
disease management is that of care planning.65
This was originally used in the management of a single disease,
diabetes, and involves the patient seeing the practice nurse
for the required tests (e.g., blood pressure and glycosylated
haemoglobin) in advance of an extended consultation with
the GP. The patient is sent the results of the tests and then asked
to prioritise their problems in anticipation of the doctor’s
appointment.
This concept can be extended to the patient with multi-
morbidities using a uniﬁed multi-disease management template
that can be tailored to the individual patient.
Such an approach has been used successfully for COPD
patients, with multimorbidities in primary care, in Bradford in
the north of England.6
A model for structured chronic disease management of the
patient with COPD and multiple comorbidities is shown in
Figure 3.
SUMMARY
● Management of the patient with multimorbidity involves
consideration of the psychosocial as well as physical problems.
● A 10-min consultation, common in the United Kingdom, can
deal with the patient’s presenting problem and can offer an
opportunity for brief health promotion (e.g., giving up
smoking), but an extended consultation time of at least
30 min, as in some European countries, is needed to deal with
complex multiple conditions.
● Although chronic disease targets and tick boxes may aid
structured reviews, considering the patient’s agenda including
shared decision-making are key to producing worthwhile
change.
● Multimorbid chronic disease management can be helped by
the use of care planning, uniﬁed disease templates, use of
information technology with appointment reminders, and help
of the wider primary care and community teams.
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